| Ceftriaxone reduces L‐dopa–induced dyskinesia severity in 6‐hydroxydopamine parkinson's disease model T Chotibut, S Meadows, EA Kasanga, T McInnis, MA Cantu, C Bishop, ... Movement Disorders 32 (11), 1547-1556, 2017 | 51 | 2017 |
| Characterizing the differential roles of striatal 5-HT1A auto-and hetero-receptors in the reduction of l-DOPA-induced dyskinesia SM Meadows, NE Chambers, MM Conti, SC Bossert, C Tasber, E Sheena, ... Experimental neurology 292, 168-178, 2017 | 45 | 2017 |
| Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia K Lanza, SM Meadows, NE Chambers, E Nuss, MM Deak, S Ferré, ... Neuropharmacology, 2018 | 42 | 2018 |
| Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats MM Conti, SM Meadows, M Melikhov-Sosin, D Lindenbach, J Hallmark, ... Neuropharmacology 110, 125-134, 2016 | 30 | 2016 |
| D‐512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti‐Parkinsonian efficacy than ropinirole in Parkinsonian rats D Lindenbach, B Das, MM Conti, SM Meadows, AK Dutta, C Bishop British journal of pharmacology 174 (18), 3058-3071, 2017 | 24 | 2017 |
| D-512, a novel dopamine D2/D3 receptor agonist, demonstrates superior anti-parkinsonian efficacy over ropinirole in parkinsonian rats D Lindenbach, B Das, MM Conti, SM Meadows, AK Dutta, C Bishop | 24* | |
| Diverse serotonin actions of vilazodone reduce l‐3, 4‐dihidroxyphenylalanine–induced dyskinesia in hemi‐parkinsonian rats SM Meadows, MM Conti, L Gross, NE Chambers, Y Avnor, CY Ostock, ... Movement Disorders 33 (11), 1740-1749, 2018 | 23 | 2018 |
| Ceftriaxone, a Beta-Lactam Antibiotic, Reduces the Severity of L-DOPA-Induced Dyskinesia in a Rat Model of Parkinson’s Disease EA Kasanga, T McInnis, T Chotibut, S Meadows, C Bishop, M Salvatore | 3 | 2017 |
| Evidence for improved motor function by ceftriaxone despite striatal tyrosine hydroxylase loss following nigrostriatal lesion EA Kasanga, S Meadows, MA Cantu, C Bishop, MF Salvatore | | 2018 |
